Literature DB >> 35881280

Functional and Metabolic Imaging in Heart Failure with Preserved Ejection Fraction: Promises, Challenges, and Clinical Utility.

Matthew K Burrage1, Andrew J Lewis1,2, Jack J J Miller3,4,5,6.   

Abstract

Heart failure with preserved ejection fraction (HFpEF) is recognised as an increasingly prevalent, morbid and burdensome condition with a poor outlook. Recent advances in both the understanding of HFpEF and the technological ability to image cardiac function and metabolism in humans have simultaneously shone a light on the molecular basis of this complex condition of diastolic dysfunction, and the inflammatory and metabolic changes that are associated with it, typically in the context of a complex patient. This review both makes the case for an integrated assessment of the condition, and highlights that metabolic alteration may be a measurable outcome for novel targeted forms of medical therapy. It furthermore highlights how recent technological advancements and advanced medical imaging techniques have enabled the characterisation of the metabolism and function of HFpEF within patients, at rest and during exercise.
© 2022. The Author(s).

Entities:  

Keywords:  C13; Cardiac metabolism; Diastolic dysfunction; HFpEF; Heart failure; Metabolic imaging; PET; Systematic review

Year:  2022        PMID: 35881280     DOI: 10.1007/s10557-022-07355-7

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.947


  147 in total

1.  Trends in prevalence and outcome of heart failure with preserved ejection fraction.

Authors:  Theophilus E Owan; David O Hodge; Regina M Herges; Steven J Jacobsen; Veronique L Roger; Margaret M Redfield
Journal:  N Engl J Med       Date:  2006-07-20       Impact factor: 91.245

Review 2.  Epidemiology and clinical course of heart failure with preserved ejection fraction.

Authors:  Carolyn S P Lam; Erwan Donal; Elisabeth Kraigher-Krainer; Ramachandran S Vasan
Journal:  Eur J Heart Fail       Date:  2010-08-03       Impact factor: 15.534

3.  Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes.

Authors:  Benjamin A Steinberg; Xin Zhao; Paul A Heidenreich; Eric D Peterson; Deepak L Bhatt; Christopher P Cannon; Adrian F Hernandez; Gregg C Fonarow
Journal:  Circulation       Date:  2012-05-21       Impact factor: 29.690

4.  Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction.

Authors:  Tialda Hoekstra; Ivonne Lesman-Leegte; Dirk J van Veldhuisen; Robbert Sanderman; Tiny Jaarsma
Journal:  Eur J Heart Fail       Date:  2011-06-28       Impact factor: 15.534

5.  Outcome of heart failure with preserved ejection fraction in a population-based study.

Authors:  R Sacha Bhatia; Jack V Tu; Douglas S Lee; Peter C Austin; Jiming Fang; Annick Haouzi; Yanyan Gong; Peter P Liu
Journal:  N Engl J Med       Date:  2006-07-20       Impact factor: 91.245

6.  Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database.

Authors:  Clyde W Yancy; Margarita Lopatin; Lynne Warner Stevenson; Teresa De Marco; Gregg C Fonarow
Journal:  J Am Coll Cardiol       Date:  2005-12-15       Impact factor: 24.094

7.  Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.

Authors:  Sanjiv J Shah; John F Heitner; Nancy K Sweitzer; Inder S Anand; Hae-Young Kim; Brian Harty; Robin Boineau; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Eldrin F Lewis; Valetin Markov; Eileen O'Meara; Bondo Kobulia; Tamaz Shaburishvili; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Rebecca Li
Journal:  Circ Heart Fail       Date:  2012-12-20       Impact factor: 8.790

8.  Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.

Authors:  Carolyn S P Lam; Peter E Carson; Inder S Anand; Thomas S Rector; Michael Kuskowski; Michel Komajda; Robert S McKelvie; John J McMurray; Michael R Zile; Barry M Massie; Dalane W Kitzman
Journal:  Circ Heart Fail       Date:  2012-08-10       Impact factor: 8.790

9.  Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.

Authors:  Brian R Lindman; Victor G Dávila-Román; Douglas L Mann; Steven McNulty; Marc J Semigran; Gregory D Lewis; Lisa de las Fuentes; Susan M Joseph; Justin Vader; Adrian F Hernandez; Margaret M Redfield
Journal:  J Am Coll Cardiol       Date:  2014-08-12       Impact factor: 24.094

10.  Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction.

Authors:  Liam Gaziano; Kelly Cho; Luc Djousse; Petra Schubert; Ashley Galloway; Yuk-Lam Ho; Katherine Kurgansky; David R Gagnon; John P Russo; Emanuele Di Angelantonio; Angela M Wood; John Danesh; John Michael Gaziano; Adam S Butterworth; Peter W F Wilson; Jacob Joseph
Journal:  ESC Heart Fail       Date:  2021-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.